Supernus Pharmaceuticals reported second-quarter 2026 revenue of $219.06 million, a 32.4% increase from a year ago and 6.84% above the Zacks Consensus Estimate of $205.04 million. Earnings per share came in at $0.54, matching the consensus estimate but down from $0.91 a year earlier. Net product sales totaled $165.7 million, exceeding the $158.76 million analyst forecast, with Qelbree contributing $89.2 million and GOCOVRI adding $37.6 million. Royalty, licensing and other revenues surged 141.4% year over year to $18 million, far surpassing the $2.5 million estimate, while collaboration revenue from ZURZUVAE reached $35.4 million. The stock has declined 7.1% over the past month, compared with a 0.2% gain for the S&P 500.
Supernus Pharmaceuticals IncQ2 revenue beat estimates and product sales exceeded forecasts, though EPS matched consensus.